口服抗血栓药物患者急性创伤大出血诊断与治疗专家共识

2021-04-10 国内急诊/重症相关专家小组(统称) 中国急救医学

创伤是世界卫生领域面临的重大难题,全球约有十分之一的死亡原因为创伤,每年死于创伤的人数超过580 万。创伤后大出血是创伤患者死亡首要的可预防因素。

中文标题:

口服抗血栓药物患者急性创伤大出血诊断与治疗专家共识

发布日期:

2021-04-10

简要介绍:

创伤是世界卫生领域面临的重大难题,全球约有十分之一的死亡原因为创伤,每年死于创伤的人数超过580 万。创伤后大出血是创伤患者死亡首要的可预防因素。抗血栓药物是易栓疾病( 如房颤、冠心病、静脉血栓栓塞性疾病等) 血栓形成和栓塞并发症的防治基石。随着人口老龄化,易栓疾病诊断和防治的进展,应用抗血栓药物的患者在不断增加。在美国,应用抗凝药物的患者已高达6 百万。抗血栓药物最常见的副作用是出血,当这些患者发生创伤时,出血的处理变得更加复杂。目前,对服用抗血栓药物患者发生创伤大出血时的处理尚缺乏高质量的临床证据,更没有形成统一的诊疗标准,无疑给临床工作带来挑战。因此,本共识旨在通过回顾相关文献和指南、整合专家意见,达成口服抗血栓药物患者发生创伤大出血的诊治共识。

相关资料下载:
[AttachmentFileName(sort=1, fileName=口服抗血栓药物患者急性创伤大出血诊断与治疗专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=641931c0022a248c, title=口服抗血栓药物患者急性创伤大出血诊断与治疗专家共识, enTitle=, guiderFrom=中国急救医学, authorId=0, author=, summary=创伤是世界卫生领域面临的重大难题,全球约有十分之一的死亡原因为创伤,每年死于创伤的人数超过580 万。创伤后大出血是创伤患者死亡首要的可预防因素。, cover=https://img.medsci.cn/20211028/1635400830788_5579292.jpg, journalId=0, articlesId=null, associationId=780, associationName=国内急诊/重症相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sat Apr 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">创伤是世界卫生领域面临的重大难题,全球约</span><span style="color: #373737;">有十分之一的死亡原因为创伤,每年死于创伤的人</span><span style="color: #373737;">数超过580 万。创伤后大出血是创伤患者死亡首</span><span style="color: #373737;">要的可预防因素。抗血栓药物是易栓疾病( 如房</span><span style="color: #373737;">颤、冠心病、静脉血栓栓塞性疾病等) 血栓形成和栓</span><span style="color: #373737;">塞并发症的防治基石。随着人口老龄化,易栓疾病</span><span style="color: #373737;">诊断和防治的进展,应用抗血栓药物的患者在不断</span><span style="color: #373737;">增加。在美国,应用抗凝药物的患者已高达6 百</span><span style="color: #373737;">万。抗血栓药物最常见的副作用是出血,当这些</span><span style="color: #373737;">患者发生创伤时,出血的处理变得更加复杂。目前,</span><span style="color: #373737;">对服用抗血栓药物患者发生创伤大出血时的处理尚</span><span style="color: #373737;">缺乏高质量的临床证据,更没有形成统一的诊疗标</span><span style="color: #373737;">准,无疑给临床工作带来挑战。因此,本共识旨在通</span><span style="color: #373737;">过回顾相关文献和指南、整合专家意见,达成口服抗</span><span style="color: #373737;">血栓药物患者发生创伤大出血的诊治共识。</span></p>, tagList=[TagDto(tagId=116664, tagName=急性创伤大出血)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=37672, guiderKeyword=急性大出血, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2708, appHits=116, showAppHits=0, pcHits=281, showPcHits=2591, likes=0, shares=13, comments=2, approvalStatus=1, publishedTime=Thu Oct 28 15:22:02 CST 2021, publishedTimeString=2021-04-10, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Oct 28 14:03:46 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 17:16:27 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=口服抗血栓药物患者急性创伤大出血诊断与治疗专家共识.pdf)])
口服抗血栓药物患者急性创伤大出血诊断与治疗专家共识.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1065849, encodeId=b70e106584933, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/fa7de37cae58485d98eccde049d944c8/0c35dbfa935743f99a097a3af080f677.jpeg, createdBy=059a1620547, createdName=huihui0728, createdTime=Mon Nov 01 16:22:19 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065173, encodeId=632610651e399, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 30 07:01:43 CST 2021, time=2021-10-30, status=1, ipAttribution=)]
    2021-11-01 huihui0728

    #学习#学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1065849, encodeId=b70e106584933, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210604/fa7de37cae58485d98eccde049d944c8/0c35dbfa935743f99a097a3af080f677.jpeg, createdBy=059a1620547, createdName=huihui0728, createdTime=Mon Nov 01 16:22:19 CST 2021, time=2021-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1065173, encodeId=632610651e399, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sat Oct 30 07:01:43 CST 2021, time=2021-10-30, status=1, ipAttribution=)]
    2021-10-30 微探

    学习学习

    0